Chapter 1 Newborn Screening for Intellectual Disability

No abstract is available for this paper.

• Publication year

  2008

• Venue

  International Review of Research in Mental Retardation

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Education, Psychology

• Identifiers
  DOI 10.1016/s0074-7750(08)00001-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Ethical issues with genetic testing in pediatrics.

  2013cited by this paper
• Supporting family adaptation to presymptomatic and "untreatable" conditions in an era of expanded newborn screening.

  2009cited by this paper
• Ethical, Legal, and Social Concerns About Expanded Newborn Screening: Fragile X Syndrome as a Prototype for Emerging Issues

  2008cited by this paper
• Editorial: thoughts on establishing research significance and preserving scientific integrity.

  2008cited by this paper
• Newborn Screening for Pompe Disease: Synthesis of the Evidence and Development of Screening Recommendations

  2007cited by this paper
• Introducing new screens: Why are we all doing different things?

  2007cited by this paper
• Newborn screening in North America

  2007cited by this paper
• Newborn screening in Latin America at the beginning of the 21st century

  2007cited by this paper
• Modeling the Impact of Formal and Informal Supports for Young Children With Disabilities and Their Families

  2007cited by this paper
• The Future of Personal Genomics

  2007cited by this paper
• Parenting children with borderline intellectual functioning: a unique risk population.

  2007cited by this paper
• Child development: risk factors for adverse outcomes in developing countries.

  2007cited by this paper
• Neonatal screening: from the ‘Guthrie age’ to the ‘genetic age’

  2007cited by this paper
• Attitudes Toward Fragile X Mutation Carrier Testing from Women Identified in a General Population Survey

  2007cited by this paper
• Newborn screening: Experiences in the Middle East and North Africa

  2007cited by this paper
• Newborn screening in the Asia Pacific region

  2007cited by this paper
• Will genomics widen or help heal the schism between medicine and public health?

  2007cited by this paper
• Expanded newborn screening in Europe 2007

  2007cited by this paper
• Child development in developing countries 3 Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world

  2007cited by this paper
• Newborn Screening Technology: Proceed With Caution

  2006cited by this paper
• A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening

  2006cited by this paper
• NICHD research initiative in newborn screening.

  2006cited by this paper
• Current status of newborn screening: decision-making about the conditions to include in screening programs.

  2006cited by this paper
• National evaluation of US newborn screening system components.

  2006cited by this paper
• Expanded Newborn Screening for Biochemical Disorders: The Effect of a False-Positive Result

  2006cited by this paper
• Mosaicism for a full mutation, premutation, and deletion of the CGG repeats results in 22% FMRP and elevated FMR1 mRNA levels in a high‐functioning fragile X male

  2006cited by this paper
• Introduction: newborn screening.

  2006cited by this paper
• State Newborn Screening in the Tandem Mass Spectrometry Era: More Tests, More False-Positive Results

  2006cited by this paper
• Quantifying the health benefits of genetic tests: The importance of a population perspective

  2006cited by this paper
• Changing perspectives on the benefits of newborn screening.

  2006cited by this paper
• The high price of false positives.

  2006cited by this paper
• Critical role of the March of Dimes in the expansion of newborn screening.

  2006cited by this paper
• Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children

  2006cited by this paper
• From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels

  2006cited by this paper
• Parenting in the genomic age: the ‘cursed blessing’ of newborn screening

  2006cited by this paper
• Recommended Outcomes for Families of Young Children with Disabilities

  2006cited by this paper
• Pediatricians' Attitudes Toward Expanding Newborn Screening

  2005cited by this paper
• Early Intervention for Children with Intellectual Disabilities: Current Knowledge and Future Prospects*

  2005cited by this paper
• Women’s Attitudes Toward Testing for Fragile X Carrier Status: A Qualitative Analysis

  2005cited by this paper
• Newborn screening for developmental disabilities: reframing presumptive benefit.

  2005cited by this paper
• Research for Newborn Screening: Developing a National Framework

  2005cited by this paper
• Does newborn screening save money? The difference between cost-effective and cost-saving interventions.

  2005cited by this paper
• Thirty-Six-Month Outcomes for Families of Children Who Have Disabilities and Participated in Early Intervention

  2005cited by this paper
• Video Analysis of Sensory-Motor Features in Infants with Fragile X Syndrome at 9–12 Months of Age

  2005cited by this paper
• Toward a biopsychosocial model for 21st-century genetics.

  2005cited by this paper
• Developmental Screening and Detection of Developmental Delays in Infants and Toddlers with Fragile X Syndrome

  2004cited by this paper
• Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.

  2004cited by this paper
• First experiences with early intervention: a national perspective.

  2004cited by this paper
• Newborn screening for fragile X syndrome.

  2004cited by this paper
• Molecular and comparative genetics of mental retardation.

  2004cited by this paper
• Screening for Fragile X Syndrome: Parent attitudes and perspectives

  2003cited by this paper
• Psychopathology in the postgenomic era.

  2003cited by this paper
• Discovering fragile X syndrome: family experiences and perceptions.

  2003cited by this paper
• Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

  2003cited by this paper
• Ethical issues raised by genetic testing with oligonucleotide microarrays

  2003cited by this paper
• How Do Primary Care Physicians Identify Young Children with Developmental Delays? A National Survey

  2003cited by this paper
• Development and Behavior of Male Toddlers With Fragile X Syndrome

  2001cited by this paper
• Identifying infants and toddlers with Fragile X syndrome: Issues and recommendations

  2001cited by this paper
• Serving the family from birth to the medical home. Newborn screening: a blueprint for the future - a call for a national agenda on state newborn screening programs

  2000cited by this paper
• The Federal Role in Early Intervention

  2000cited by this paper
• Family Experiences and Factors Associated with the Diagnosis of Fragile X Syndrome

  2000cited by this paper
• Historical aspects and overview of research on phenylketonuria

  1999cited by this paper
• Early experience and early intervention for children “at risk”for developmental delay and mental retardation

  1999cited by this paper
• Early intervention as we know it

  1999cited by this paper
• Mutational analysis using oligonucleotide microarrays

  1999cited by this paper
• Genetics of autism

  1998cited by this paper
• Genetics of specific reading disability

  1996cited by this paper
• Intellectual Development and Academic Achievement of Children Treated Early for Phenylketonuria

  1979cited by this paper

• No citing papers are available for this paper.